|Description||A metabolite of Gefitinib.|
Biochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of ...
PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It reduces inflammatory pain via a cannabinoid receptor-dependent mechanism.
FAAH inhibitor 1
Time-dependent preincubation study of FAAH inhibitor 1 was consistent with it being a reversible inhibitor. Activity-based protein-profiling (ABPP) evaluation o...
JZL195 is a potent dual inhibitor of Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), enzymes that degrade the endocannabinoids 2-arachidon...
A metabolite of Gefitinib.
PF-04457845 is a potent and exquisitely selective inhibitor of FAAH, with an IC50 of 7.2 nM, and both analgesic and antiinflammatory effects in animal studies c...
OL135 is a CNS penetrant, highly potent and selective reversible inhibitor of FAAH. It exhibits analgesic pharmacology in various animal models without the moto...
JNJ-40355003 is a selective fatty acid amide hydrolase (FAAH) inhibitor. JNJ-40355003 can elevate the plasma levels of anandamide, oleoyl ethanolamide, and palm...
LY2183240 is a novel and highly potent blocker of anandamide uptake. It inhibits fatty acid amide hydrolase (FAAH) activity. It increases brain anandamide conce...
JNJ-42165279 is a fatty acid amide hydrolase (FAAH) inhibitor developed by Janssen Pharmaceutica and IC50 value is 70 nM. It is described as a covalently bindin...
This active molecular is a reversible FAAH (fatty acid amide hydrolase) inhibitor that increases levels of the neurotransmitter anandamide in the central nervou...
URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.